ALX Oncology (NASDAQ:ALXO) announced its quarterly earnings data on Tuesday. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.01, Zacks reports.
Shares of ALX Oncology stock opened at $70.64 on Friday. The firm’s fifty day moving average is $42.38. ALX Oncology has a 12-month low of $28.01 and a 12-month high of $73.21.
Several analysts have commented on ALXO shares. Jefferies Financial Group started coverage on shares of ALX Oncology in a research report on Tuesday, August 11th. They issued a “buy” rating and a $50.00 price objective on the stock. Piper Sandler lifted their price objective on shares of ALX Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday. Lifesci Capital reaffirmed an “outperform” rating on shares of ALX Oncology in a research report on Wednesday, September 30th. Cantor Fitzgerald began coverage on shares of ALX Oncology in a research note on Tuesday, August 11th. They issued an “overweight” rating for the company. Finally, Credit Suisse Group began coverage on shares of ALX Oncology in a research report on Tuesday, August 11th. They set an “outperform” rating and a $53.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $57.67.
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma.
Featured Story: Example of operating income, EBIT and EBITDA
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.